文献速递脊柱关节炎

司库奇尤单抗治疗608例银屑病关节炎患者的24个月真实世界前瞻性多中心研究

Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
PubMed 文献 · RMD Open · 2021-01-01

该研究在意大利多中心前瞻性队列中评估司库奇尤单抗治疗银屑病关节炎的24个月有效性、安全性及药物留存率。608例患者中37.34%为生物制剂初治,62.66%为多线失败;司库奇尤单抗显示多领域疗效改善,T24时初治组MDA达75.71%、多线失败组70.37%,总体留存率71%。

要点

  • 司库奇尤单抗在真实世界中改善PsA多个疾病活动指标,T24时ASDAS和DAPSA均显著下降。
  • T24时生物制剂初治组在PASI、ESR、CRP和关节计数方面优于多线失败组。
  • 总体药物留存率T24为71%,停药主要因原发/继发失效,22例因不良事件停药。

核心结论

  • 在真实临床环境中,司库奇尤单抗对所有PsA领域安全有效,药物留存率可观。

研究设计与样本

  • 意大利多中心前瞻性队列研究,连续纳入608例接受司库奇尤单抗治疗的银屑病关节炎患者,随访24个月。
  • 按生物制剂治疗线数分组:初治组(A组)227例(37.34%),多线失败组(B组)381例(62.66%)。
  • 在基线(T0)、6个月(T6)、12个月(T12)和24个月(T24)记录疾病活动度、功能、临床计量评分及生化指标。

主要发现

  • ASDAS从T0的3.26(0.88)降至T24的1.60(0.69),p=0.02。
  • DAPSA从T0的25.29(11.14)降至T24的7.69(4.51),p<0.01。
  • T24时A组PASI(p=0.04)、ESR(p=0.03)、CRP(p=0.05)和关节计数(p=0.03)均低于B组。
  • T24时MDA达标率:A组75.71%,B组70.37%。
  • 123例(20.23%)停药,主要因原发/继发失效,22例因不良事件停药;T24总体留存率71%,留存率因司库奇尤单抗剂量(p=0.004)和性别(p=0.05)存在差异。

临床怎么用

  • 司库奇尤单抗可作为PsA的有效治疗选择,生物制剂初治患者在多方面结局上可能更优。
  • 真实世界中需关注剂量和性别对药物留存率的影响,并监测失效及不良事件导致的停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety of secukinumab, (2) the drug retention rate and minimal disease activity (MDA), (3) differences in the outcomes according to the biological treatment line: biologic-naïve patients (group A) versus multifailure (group B) patients. METHODS: Consecutive patients with PsA receiving secukinumab were evaluated prospectively. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were collected. Disease activity/functional/clinimetric scores and biochemical values were recorded at baseline (T0), 6(T6), 12(T12) and 24(T24) months. Effectiveness was evaluated overtime with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug-discontinuation and MDA at T6. Infections and adverse events were recorded. RESULTS: 608 patients (41.28% men; mean (SD) age 52.78 (11.33)) were enrolled; secukinumab was prescribed as first-line biological treatment in 227 (37.34%) patients, as second (or more)-line biological treatment in 381 (62.66%). Effectiveness of secukinumab was shown with an improvement in several outcomes, such as Ankylosing Spondylitis Disease Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) and Disease Activity Index for Psoriatic Arthritis (T0=25.29 (11.14) vs T24=7.69 (4.51); p<0.01). At T24, group A showed lower Psoriasis Area Severity Index (p=0.04), erythrocyte sedimentation rate and C reactive protein (p=0.03 ;p=0.05) and joint count (p=0.03) compared with group B. At T24, MDA was achieved in 75.71% of group A and 70.37% of group B. Treatment was discontinued in 123 (20.23%) patients, mainly due to primary/secondary loss of effectiveness, and in 22 due to adverse events. Retention rate at T24 was 71% in the whole population, with some difference depending on secukinumab dosage (p=0.004) and gender (p=0.05). CONCLUSIONS: In a real-life clinical setting, secukimumab proved safe and effective in all PsA domains, with notable drug retention rate.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021. PMID: 33593933. doi:10.1136/rmdopen-2020-001519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。